ArticleJournal of cardiothoracic surgery2026
EGF-supplemented decellularized tracheal matrix hydrogels promote tracheal defect repair.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTracheal defect repair is a major clinical challenge in thoracic surgery, with long-segment defects having a low clinical repair rate. Autologous cartilage transplantation is limited by high postoperative stenosis and insufficient autologous tissue, while traditional artificial tracheal materials have poor biocompatibility and no epithelial regeneration-inducing capacity, leading to poor long-term efficacy. This study aimed to fabricate a biomimetic composite hydrogel and evaluate its physicochemical properties and tracheal repair efficacy, providing a new tissue-engineered strategy for clinical tracheal defect management.
methodsA PEGDA/DCM/EGF composite hydrogel was prepared via photopolymerization. Its physicochemical properties and EGF release pattern were characterized. In vitro experiments on rat tracheal epithelial cells assessed cell viability, proliferation and migration. A tracheal defect model was established in SD rats, with the hydrogel implanted; gross observation, HE staining and immunohistochemistry were performed at 2 weeks post-implantation to evaluate repair efficacy, with statistical methods used for intergroup comparisons.
resultsThe PEGDA/DCM hydrogel had optimized microstructure and mechanical properties matching native trachea, maintained structural stability under physiological conditions, and achieved sustained EGF release without burst effect. The PEGDA/DCM/EGF hydrogel significantly promoted the viability, proliferation and migration of rat tracheal epithelial cells in vitro. In vivo, implanted SD rats had intact tracheal architecture and unobstructed lumens at 2 weeks; HE staining and immunohistochemistry confirmed continuous epithelial layer formation and successful epithelialization at the defect site.
conclusionsThe PEGDA/DCM/EGF composite hydrogel has favorable physicochemical properties, excellent biocompatibility and effective tracheal repair efficacy, with DCM optimizing hydrogel performance and sustained EGF release accelerating epithelial regeneration. This study provides a promising tissue-engineered strategy for tracheal defect repair, with significant clinical translation potential for thoracic surgery clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.